Abstract
Background: Cholangiocarcinoma (CCA) represents the second most common primary liver cancer and is characterized by a very poor outcome, but reliable prognostic markers are largely missing. Sarcopenia, the progressive loss of muscle mass and strength, as well as myosteatosis have been associated with an unfavorable outcome in several clinical conditions, including cancer. Here, we evaluated the prognostic relevance of sarcopenia and myosteatosis using routine abdominal CT (computed tomography) scans in advanced stage CCA patients undergoing palliative treatment. Methods: Routine abdominal CT scans were used to assess the skeletal muscle and the psoas muscle index (L3SMI/L3PMI) at the level of the third lumbar vertebra as radiological indices for sarcopenia as well as the mean skeletal muscle attenuation (MMA) as a surrogate for myosteatosis. Results were correlated with clinical data and outcomes. Results: Using a calculated optimal cut-off value of 71.95 mm2/cm, CCA patients with an L3SMI value below this cut-off showed a significantly reduced median overall survival (OS) of only 250 days compared to 450 days in patients with a higher L3SMI. Moreover, the median OS of CCA patients with an L3PMI above 6345 mm2/cm was 552 days compared to 252 days in patients with a lower L3PMI. Finally, CCA patients with an MMA above 30.51 Hounsfield Units survived significantly longer (median OS: 430 days) compared to patients with an MMA value below this ideal cut-off (median OS: 215 days). The prognostic relevance of L3SMI, L3PMI, and MMA was confirmed in uni- and multivariate Cox regression analyses. Conclusion: Routine abdominal CT scans represent a unique opportunity to evaluate sarcopenia as well as myosteatosis in advanced CCA patients. We identified the L3SMI/L3PMI as well as the MMA as negative prognostic factors in CCA patients undergoing palliative therapy, arguing that the “opportunistic” evaluation of these parameters might yield important clinical information in daily routine.
Highlights
Cholangiocarcinoma (CCA) is the second most common primary malignancy of the liver and is characterized by a very poor outcome [1]
CCA patients with an mean skeletal muscle attenuation (MMA) above 30.51 Hounsfield Units (HU) lived significantly longer compared to patients with an MMA value below this ideal cut-off (430 days (95%CI: 234–626) vs. 215 days (95%CI: 88–342); log rank χ2 (1) = 6.709, p = 0.010; Figure 5A)
An MMA value below the ideal cut-off value represented a negative prognostic factor for overall survival (OS) (HR 2.384, 95%CI: 1.054–5.393, p = 0.037, independent of CRP, thrombocytes, used tumor markers and CA19-9)of as
Summary
Cholangiocarcinoma (CCA) is the second most common primary malignancy of the liver and is characterized by a very poor outcome [1]. While surgical tumor resection represents a potentially curative therapeutic option in patients with early tumor stages, patients with locally advanced or metastatic CCA are usually attributed to a palliative treatment approach including systemic chemotherapy or active symptom control (ASC) in case of a poor clinical performance status [2]. The combination of gemcitabine and cisplatin has been established as the standard first-line therapy for unresectable CCA patients and significantly improves the median overall survival (OS) to 11.7 months [3]. Cholangiocarcinoma (CCA) represents the second most common primary liver cancer and is characterized by a very poor outcome, but reliable prognostic markers are largely missing. We evaluated the prognostic relevance of sarcopenia and myosteatosis using routine abdominal CT (computed tomography) scans in advanced stage CCA patients undergoing palliative treatment
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
